Hospitalization for Invasive Pneumococcal Diseases in Young Children before Use of 13-Valent Pneumococcal Conjugate Vaccine, Suzhou, China

Emerg Infect Dis. 2021 Jan;27(1):69-75. doi: 10.3201/eid2701.181415.

Abstract

A 13-valent pneumococcal conjugate vaccine against invasive pneumococcal disease (IPD) was introduced in China in April 2017. We describe 105 children <5 years of age who were hospitalized for IPD at Soochow University Affiliated Children's Hospital in Suzhou, China, during January 2010-December 2017. We calculated the incidence of hospitalization for IPD as 14.55/100,000 children in Suzhou. We identified 8 different capsular serotypes: 6B (28.4% of cases), 14 (18.9% of cases), 19A (18.9% of cases), 19F (12.2% of cases), 23F (10.8% of cases), 20 (4.1% of cases), 9V (4.1% of cases), and 15B/C (2.7% of cases). These results provide baseline data of IPD before the introduction of this vaccine in China, enabling researchers to better understand its effects on IPD incidence.

Keywords: China; Invasive pneumococcal diseases; PCV13; PCV7; Streptococcus pneumoniae; Suzhou; bacteria; hospitalization; incidence of hospitalization; meningitis; pneumococcal conjugate vaccines; streptococci; vaccines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Child
  • Child, Preschool
  • China / epidemiology
  • Hospitalization
  • Humans
  • Incidence
  • Infant
  • Pneumococcal Infections* / epidemiology
  • Pneumococcal Infections* / prevention & control
  • Pneumococcal Vaccines
  • Streptococcus pneumoniae*
  • Vaccines, Conjugate

Substances

  • Pneumococcal Vaccines
  • Vaccines, Conjugate